Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology – non-motor symptoms

Abstract

The treatment of Parkinson's disease (PD) is a challenge, especially because it is considered highly individualized. The Brazilian Academy of Neurology (ABN) has identified the need to disseminate knowledge about its management, adapting the best evidence to the Brazilian population. The present article aims to report the recommendations for the treatment of non-motor symptoms of PD, developed by a group of specialists in movement disorders from the ABN's scientific department. In 2021, the first part, referring to the motor symptoms of PD, was published. The main non-motor symptoms were addressed—among them neuropsychiatric symptoms, such as depression, anxiety, cognitive alteration, and psychosis—as well as the possible recommended therapies and medications used to control pain, sleep disorders, and dysautonomia.

Keywords

Parkinson Disease - Dementia - Autonomic Nervous System Diseases - Pain

Authors' Contributions

DPM, RAS: lead writers of the original draft, manuscript and editing; RGC, FECC: critical review of the manuscript. The other authors contributed equally to the writing of the manuscript.

Editor-in-Chief: Hélio A. G. Teive.

Associate Editor: Renato Puppi Munhoz.

Publikationsverlauf

Eingereicht: 05. August 2024

Angenommen: 10. Oktober 2024

Artikel online veröffentlicht:
24. Februar 2025

• References

• 1 Saba RA, Maia DP, Cardoso FEC. et al. Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms. Arq Neuropsiquiatr 2022; 80 (03) 316-329
• 2 Gronseth GS, Cox J, Gloss D. et al. On behalf of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. 2017. Clinical Practice Guideline Process Manual, 2017 ed. 2017 Edition.
• 3 Emre M, Aarsland D, Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22 (12) 1689-1707, quiz 1837
• 4 Litvan I, Goldman JG, Tröster AI. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27 (03) 349-356
• 5 Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23 (06) 837-844
• 6 Parmera JB, Tumas V, Ferraz HB. et al. Diagnosis and management of Parkinson's disease dementia and dementia with Lewy bodies: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol 2022; 16 (3, Suppl 1) 73-87
• 7 Sawada H, Oeda T, Kohsaka M. et al. Early-start vs delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial. Expert Opin Pharmacother 2021; 22 (03) 363-371
• 8 Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 2015; 7 (01) 4
• 9 Sawada H, Oeda T, Kohsaka M. et al. Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years. J Neurol Neurosurg Psychiatry 2018; 89 (12) 1332-1340
• 10 Mori E, Ikeda M, Nakagawa M, Miyagishi H, Yamaguchi H, Kosaka K. Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies. Dement Geriatr Cogn Disord 2015; 40 (3-4): 186-198
• 11 Li Z, Yu Z, Zhang J. et al. Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients. Eur Neurol 2015; 74 (1-2): 86-91
• 12 Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord 2015; 30 (07) 912-918
• 13 Wang HF, Yu JT, Tang SW. et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86 (02) 135-143
• 14 Pagano G, Rengo G, Pasqualetti G. et al. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015; 86 (07) 767-773
• 15 Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med 2019; 17 (03) 1611-1624
• 16 Watts KE, Storr NJ, Barr PG, Rajkumar AP. Systematic review of pharmacological interventions for people with Lewy body dementia. Aging Ment Health 2023; 27 (02) 203-216
• 17 Knight R, Khondoker M, Magill N, Stewart R, Landau S. A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia. Dement Geriatr Cogn Disord 2018; 45 (3-4): 131-151
• 18 Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015; 30 (01) 46-54
• 19 Aarsland D, Ballard C, Walker Z. et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8 (07) 613-618
• 20 Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. MODERATO Investigators. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord 2016; 31 (05) 709-714
• 21 Frakey LL, Friedman JH. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia. J Neuropsychiatry Clin Neurosci 2017; 29 (01) 22-25
• 22 Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23 (02) 183-189, quiz 313
• 23 Richard IH, McDermott MP, Kurlan R. et al; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78 (16) 1229-1236
• 24 Menza M, Dobkin RD, Marin H. et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72 (10) 886-892
• 25 Devos D, Dujardin K, Poirot I. et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23 (06) 850-857
• 26 Seppi K, Ray Chaudhuri K, Coelho M. et al; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord 2019; 34 (02) 180-198
• 27 Barone P, Poewe W, Albrecht S. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9 (06) 573-580
• 28 Jiang DQ, Jiang LL, Wang Y, Li MX. The role of pramipexole in the treatment of patients with depression and Parkinson's disease: A meta-analysis of randomized controlled trials. Asian J Psychiatr 2021; 61: 102691
• 29 Dissanayaka NN, Forbes EJ, Perepezko K. et al. Phenomenology of atypical anxiety disorders in Parkinson's disease: a systematic review. Am J Geriatr Psychiatry 2022; 30 (09) 1026-1050
• 30 Weintraub D, Aarsland D, Biundo R, Dobkin R, Goldman J, Lewis S. Management of psychiatric and cognitive complications in Parkinson's disease. BMJ 2022; 379: e068718
• 31 Schneider RB, Auinger P, Tarolli CG, Iourinets J, Gil-Díaz MC, Richard IH. A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability. Parkinsonism Relat Disord 2020; 81: 69-74
• 32 Grimes D, Fitzpatrick M, Gordon J. et al. Canadian guideline for Parkinson disease. CMAJ 2019; 191 (36) E989-E1004
• 33 Ferreira JJ, Katzenschlager R, Bloem BR. et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20 (01) 5-15
• 34 Lieberman JA, Tasman A. Handbook of Psychiatric drugs. West Sussex. England: John Wiley & Sons; 2006
• 35 Pollak P, Tison F, Rascol O. et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75 (05) 689-695
• 36 Srisurapanont M, Suradom C, Suttajit S, Kongsaengdao S, Maneeton B. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis. Gen Hosp Psychiatry 2024; 87: 124-133
• 37 Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340 (10) 757-763
• 38 The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353 (9169): 2041-2042
• 39 Breier A, Sutton VK, Feldman PD. et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52 (05) 438-445
• 40 Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995; 7 (04) 471-475
• 41 Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16 (01) 135-139
• 42 Wolters EC, Hurwitz TA, Mak E. et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40 (05) 832-834
• 43 Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17 (04) 676-681
• 44 Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18 (05) 510-514
• 45 Juncos JL, Roberts VJ, Evatt ML. et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19 (01) 29-35
• 46 Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 2006; 253 (02) 171-175
• 47 Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20 (08) 958-963
• 48 Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007; 22 (03) 313-318
• 49 Morgante L, Epifanio A, Spina E. et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27 (04) 153-156
• 50 Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29 (06) 331-337
• 51 Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55 (06) 789-794
• 52 Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17 (05) 1031-1035
• 53 Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15 (02) 301-304
• 54 Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15 (06) 1230-1237
• 55 Debove I, Paschen S, Amstutz D. et al; and the Members of the ICBD in PD Management Consensus Group. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus. Mov Disord 2024; 39 (02) 235-248
• 56 Fenu S, Wardas J, Morelli M. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol 2009; 20 (5-6): 363-379
• 57 Lester J, Gonzalez-Aleman G, Zuniga-Ramirez C, Diaz-Pascuali SP, Raina-Castellino GB, Micheli-Gould F. [Pathological gambling associated with pramipexole use in Parkinson's disease]. Rev Neurol 2006; 43 (05) 316-318
• 58 Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68 (03) 400-404
• 59 Chung S, Bohnen NI, Albin RL, Frey KA, Müller MLTM, Chervin RD. Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. J Clin Sleep Med 2013; 9 (11) 1131-1137
• 60 Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol 1998; 245 (Suppl. 01) S15-S18
• 61 Hadi F, Agah E, Tavanbakhsh S. et al. Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. Neurol Sci 2022; 43 (10) 6141-6148
• 62 Menza M, Dobkin RD, Marin H. et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010; 25 (11) 1708-1714
• 63 Pierantozzi M, Placidi F, Liguori C. et al. Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med 2016; 21: 140-144
• 64 Trenkwalder C, Kies B, Rudzinska M. et al; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26 (01) 90-99
• 65 Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005; 6 (05) 459-466
• 66 Medeiros CAM, Carvalhedo de Bruin PF, Lopes LA, Magalhães MC, de Lourdes Seabra M, de Bruin VMS. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254 (04) 459-464
• 67 Schrempf W, Fauser M, Wienecke M. et al. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial. Eur J Neurol 2018; 25 (04) 672-679
• 68 Avila A, Cardona X, Martin-Baranera M. et al. Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction. J Clin Psychopharmacol 2015; 35 (06) 719-723
• 69 Shen Y, Lv QK, Xie WY. et al. Circadian disruption and sleep disorders in neurodegeneration. Transl Neurodegener 2023; 12 (01) 8
• 70 Shen Y, Huang JY, Li J, Liu CF. Excessive daytime sleepiness in Parkinson's disease: clinical implications and management. Chin Med J (Engl) 2018; 131 (08) 974-981
• 71 Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 2011; 25 (03) 203-212
• 72 Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57 (08) 1392-1396
• 73 Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15 (04) 658-663
• 74 Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18 (06) 659-667
• 75 Högl B, Saletu M, Brandauer E. et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25 (08) 905-909
• 76 Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76 (12) 1636-1639
• 77 Roth T, Schwartz JRL, Hirshkowitz M, Erman MK, Dayno JM, Arora S. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med 2007; 3 (06) 595-602
• 78 Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007; 22 (14) 2070-2076
• 79 Devos D, Krystkowiak P, Clement F. et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78 (05) 470-475
• 80 Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis. Parkinsonism Relat Disord 2016; 27: 25-34
• 81 Dauvilliers Y, Schenck CH, Postuma RB. et al. REM sleep behaviour disorder. Nat Rev Dis Primers 2018; 4 (01) 19
• 82 Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996; 100 (03) 333-337
• 83 Li SX, Lam SP, Zhang J. et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med 2016; 21: 114-120
• 84 Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 2010; 19 (04) 591-596
• 85 During EH, Hernandez B, Miglis MG. et al. Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder. Sleep 2023; 46 (08) zsad103
• 86 Plastino M, Gorgone G, Fava A. et al. Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study. J Clin Neurosci 2021; 91: 306-312
• 87 Kashihara K, Nomura T, Maeda T. et al. Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial. Intern Med 2016; 55 (03) 231-236
• 88 de Almeida CMO, Brito MMC, Bosaipo NB. et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Mov Disord 2021; 36 (07) 1711-1715
• 89 Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology 2003; 61 (10) 1418-1420
• 90 Wang Y, Yang Y, Wu H, Lan D, Chen Y, Zhao Z. Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease. J Clin Sleep Med 2016; 12 (10) 1403-1409
• 91 Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55 (06) 870-871
• 92 Bamford CR. Carbamazepine in REM sleep behavior disorder. Sleep 1993; 16 (01) 33-34
• 93 Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord 2012; 27 (04) 559-561
• 94 Allen RP, Picchietti DL, Garcia-Borreguero D. et al; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med 2014; 15 (08) 860-873
• 95 Winkelmann J, Allen RP, Högl B. et al. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)^§ . Mov Disord 2018; 33 (07) 1077-1091
• 96 Allen RP, Picchietti DL, Auerbach M. et al; International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 2018; 41: 27-44
• 97 Högl B, Garcia-Borreguero D, Trenkwalder C. et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 2011; 12 (04) 351-360
• 98 Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006; 21 (09) 1404-1410
• 99 Oertel W, Trenkwalder C, Beneš H. et al; SP710 study group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011; 10 (08) 710-720
• 100 Garcia-Borreguero D, Silber MH, Winkelman JW. et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 2016; 21: 1-11
• 101 Allen RP, Chen C, Garcia-Borreguero D. et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014; 370 (07) 621-631
• 102 Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59 (10) 1573-1579
• 103 Inoue Y, Uchimura N, Kuroda K, Hirata K, Hattori N. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36 (02) 251-257
• 104 Inoue Y, Hirata K, Uchimura N, Kuroda K, Hattori N, Takeuchi M. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin 2013; 29 (01) 13-21
• 105 Walters AS, Wagner ML, Hening WA. et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16 (04) 327-332
• 106 de Almeida CMO, Brito MMC, Bosaipo NB. et al. The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. Cannabis Cannabinoid Res 2023; 8 (02) 374-378
• 107 Trotti LM, Becker LA. Iron for the treatment of restless legs syndrome. Cochrane Database Syst Rev 2019; 1 (01) CD007834
• 108 Zhou X, Du J, Liang Y. et al. The Efficacy and Safety of Pharmacological Treatments for Restless Legs Syndrome: Systemic Review and Network Meta-Analysis. Front Neurosci 2021; 15: 751643
• 109 Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011; 12 (09) 906-913
• 110 Yu Q, Hu X, Zheng T. et al. Obstructive sleep apnea in Parkinson's disease: A prevalent, clinically relevant and treatable feature. Parkinsonism Relat Disord 2023; 115: 105790
• 111 Sun AP, Liu N, Zhang YS, Zhao HY, Liu XL. The relationship between obstructive sleep apnea and Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2020; 41 (05) 1153-1162
• 112 Gros P, Mery VP, Lafontaine AL. et al. Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime. Sleep Breath 2016; 20 (01) 205-212
• 113 Crosta F, Desideri G, Marini C. Obstructive sleep apnea syndrome in Parkinson's disease and other parkinsonisms. Funct Neurol 2017; 32 (03) 137-141
• 114 Harmell AL, Neikrug AB, Palmer BW. et al. Obstructive Sleep Apnea and Cognition in Parkinson's disease. Sleep Med 2016; 21: 28-34
• 115 Kaminska M, Mery VP, Lafontaine AL. et al. Change in Cognition and Other Non-Motor Symptoms With Obstructive Sleep Apnea Treatment in Parkinson Disease. J Clin Sleep Med 2018; 14 (05) 819-828
• 116 Neikrug AB, Liu L, Avanzino JA. et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep 2014; 37 (01) 177-185
• 117 Lou JS. Physical and mental fatigue in Parkinson's disease: epidemiology, pathophysiology and treatment. Drugs Aging 2009; 26 (03) 195-208
• 118 Lim TT, Kluger BM, Rodriguez RL. et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Mov Disord 2015; 30 (13) 1825-1830
• 119 Kluger BM, Rakowski D, Christian M. et al. Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease. Mov Disord 2016; 31 (07) 1027-1032
• 120 Broen MPG, Braaksma MM, Patijn J, Weber WEJ. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord 2012; 27 (04) 480-484
• 121 Rukavina K, Batzu L, Boogers A, Abundes-Corona A, Bruno V, Chaudhuri KR. Non-motor complications in late stage Parkinson's disease: recognition, management and unmet needs. Expert Rev Neurother 2021; 21 (03) 335-352
• 122 Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007; 30 (04) 201-205
• 123 Iwaki H, Ando R, Tada S. et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease. J Neurol Sci 2020; 414: 116833
• 124 Kassubek J, Chaudhuri KR, Zesiewicz T. et al. Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol 2014; 14: 42
• 125 Rascol O, Zesiewicz T, Chaudhuri KR. et al. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. J Clin Pharmacol 2016; 56 (07) 852-861
• 126 Borgohain R, Szasz J, Stanzione P. et al; Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 2014; 29 (02) 229-237
• 127 Schapira A, Fox S, Hauser R, Jankovic J, Kulisevsky J, Pahwa R. et al. SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's disease (poster). Mov Disord 2010; 25: S308
• 128 Cattaneo C, Barone P, Bonizzoni E, Sardina M. Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. J Parkinsons Dis 2017; 7 (01) 95-101
• 129 Trenkwalder C, Chaudhuri KR, Martinez-Martin P. et al; PANDA study group. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2015; 14 (12) 1161-1170
• 130 Brefel-Courbon C, Harroch E, Marques A. et al. Oxycodone or Higher Dose of Levodopa for the treatment os parkinsonian Central Pain: OXYDOPA trial. Mov Disord 2024; 39 (09) 1533-1543
• 131 Colloca L, Ludman T, Bouhassira D. et al. Neuropathic pain. Nat Rev Dis Primers 2017; 3: 17002
• 132 Perez Lloret S, Amaya M, Merello M. Pregabalin-induced parkinsonism: a case report. Clin Neuropharmacol 2009; 32 (06) 353-354
• 133 Yu SW, Lin SH, Tsai CC. et al. Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson's Disease. Front Neurol 2019; 10: 1114
• 134 Di Luca DG, Gilmour GS, Fearon C. et al. A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease. Mov Disord Clin Pract 2023; 10 (07) 1114-1119
• 135 Nguy V, Barry BK, Moloney N. et al. Exercise-induced hypoalgesia is present in people with Parkinson's disease: Two observational cross-sectional studies. Eur J Pain 2019; 23 (07) 1329-1339
• 136 Palma JA, Kaufmann H. Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. Semin Neurol 2020; 40 (05) 523-539
• 137 Gibbons CH, Schmidt P, Biaggioni I. et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017; 264 (08) 1567-1582
• 138 Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res 2016; 26 (04) 269-277
• 139 Kaufmann H, Freeman R, Biaggioni I. et al; NOH301 Investigators. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014; 83 (04) 328-335
• 140 Schindler A, Pizzorni N, Cereda E. et al. Consensus on the treatment of dysphagia in Parkinson's disease. J Neurol Sci 2021; 430: 120008
• 141 Gandhi P, Steele CM. Effectiveness of Interventions for Dysphagia in Parkinson Disease: A Systematic Review. Am J Speech Lang Pathol 2022; 31 (01) 463-485
• 142 Isaacson J, Patel S, Torres-Yaghi Y, Pagán F. Sialorrhea in Parkinson's disease. Toxins (Basel) 2020; 12 (11) 691
• 143 Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 2018; 33 (03) 372-390
• 144 Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis. CNS Drugs 2019; 33 (03) 225-238
• 145 Zesiewicz TA, Evatt M, Vaughan CP. et al; Non-Motor Working Group of the Parkinson Study Group (PSG). Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (05) 514-520
• 146 Abraham DS, Pham Nguyen TP, Newcomb CW. et al. Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease. Parkinsonism Relat Disord 2023; 115 (Oct): 105822
• 147 Giannantoni A, Conte A, Proietti S. et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol 2011; 186 (03) 960-964
• 148 Williams LJ, Griffith J, Waller SE, Kwan VP, Fung VSC. The profound impact of gastrointestinal stasis on levodopa response in Parkinson's disease. Mov Disord Clin Pract 2022; 9 (03) 394-396
• 149 Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH. Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis 2022; 8 (01) 31
• 150 Zangaglia R, Martignoni E, Glorioso M. et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007; 22 (09) 1239-1244
• 151 Pedrosa Carrasco AJ, Timmermann L, Pedrosa DJ. Management of constipation in patients with Parkinson's disease. NPJ Parkinsons Dis 2018; 4: 6
• 152 Ondo WG, Kenney C, Sullivan K. et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012; 78 (21) 1650-1654
• 153 Barichella M, Pacchetti C, Bolliri C. et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology 2016; 87 (12) 1274-1280
• 154 Tan AH, Lim SY, Chong KKA. et al. Probiotics for constipation in Parkinson disease: A randomized placebo-controlled study. Neurology 2021; 96 (05) e772-e782
• 155 Ibrahim A, Ali RAR, Manaf MRA. et al. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial. PLoS One 2020; 15 (12) e0244680
• 156 McClurg D, Walker K, Aitchison P. et al. Abdominal Massage for the Relief of Constipation in People with Parkinson's: A Qualitative Study. Parkinsons Dis 2016; 2016: 4842090
• 157 Freitas ME, Alqaraawi A, Lang AE, Liu LWC. Linaclotide and Prucalopride for Management of Constipation in Patients with Parkinsonism. Mov Disord Clin Pract 2018; 5 (02) 218-220
• 158 Si K, Ito M, Matsuba K, Shimono T. The effects of lactulose on constipation in patients with Parkinson's disease: An exploratory pilot study. Neurol Sci 2024; 10: 35
• 159 Soliman H, Coffin B, Gourcerol G. Gastroparesis in Parkinson disease: pathophysiology and clinical management. Brain Sci 2021; 11 (07) 831
• 160 Skjærbæk C, Knudsen K, Horsager J, Borghammer P. Gastrointestinal dysfunction in Parkinson's disease. J Clin Med 2021; 10 (03) 493
• 161 Soykan I, Sarosiek I, Shifflett J, Wooten GF, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12 (06) 952-957
• 162 Raciti L, De Cola MC, Ortelli P. et al. Sexual dysfunction in Parkinson disease: a multicenter Italian cross-sectional study on a still overlooked problem. J Sex Med 2020; 17 (10) 1914-1925
• 163 Pfeiffer RF. Autonomic dysfunction in Parkinson's disease. Neurotherapeutics 2020; 17 (04) 1464-1479
• 164 Bronner G, Korczyn AD. The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. Mov Disord Clin Pract 2017; 5 (01) 6-13
• 165 Bernard BA, Metman LV, Levine L, Ouyang B, Leurgans S, Goetz CG. Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. Mov Disord Clin Pract 2016; 4 (03) 412-415
• 166 Okun MS, Walter BL, McDonald WM. et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol 2002; 59 (11) 1750-1753
• 167 Margolesky J, Betté S, Singer C. Management of urologic and sexual dysfunction in Parkinson disease. Clin Geriatr Med 2020; 36 (01) 69-80